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p53 is the most studied human protein because of its role in maintaining genomic stability.
Binding to genomic targets is essential for transcription-dependent p53 tumor suppression,
but how p53 selects targets remains unclear. Here, the impact of chromatin context
on p53 genome-wide binding and targets selection is discussed. It is proposed that
p53 genomic binding serves not only to regulate transcription, but to sense epigenomic
changes threatening the genomic integrity. The problem of p53 navigating the human
genome is discussed with respect to the degenerate p53 binding motif. This discussion
relates to the fundamental problem of DNA binding factors navigating large genomes in
search for cognate binding sites.
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35 YEARS p53
p53 guards the genome by mobilizing a complex network of target
genes and coordinating the cellular stress responses to prevent
propagation of damaged DNA (Vogelstein et al., 2000). DNA
binding is important for the p53 tumor suppression; 90% of
the cancer-associated p53 mutations reside in the DNA binding
domain (Hollstein et al., 1991). It is commonly viewed that
in absence of stress cells keep low amount of p53, bound to
some genomic targets without affecting transcription, while upon
DNA damage activation, the genomic binding is accompanied by
transcription regulation. Depending on the cell type and damage,
p53 regulates different sets of genes, triggering cell cycle arrest,
DNA repair, senescence, or apoptosis, steering the cells toward
life or death (Vousden and Lu, 2002). How p53 selects its targets
remains one of the foremost questions in the field.
Binding to DNA and transcription regulation are affected
by the p53 mutational load (Leroy et al., 2014), extensive post-
translational modifications (Meek and Anderson, 2009), tertiary
structure and oligomerization state (Joerger and Fersht, 2010),
binding partners and cooperativity (Braithwaite et al., 2006; Brandt
et al., 2012), basal transcription machinery (Espinosa, 2008), and
genomic binding sites (Horvath et al., 2007; Riley et al., 2008; Wang
et al., 2009). Adding to this complexity, the family members p63
and p73 (Belyi et al., 2010) and the isoforms expression patterns in
the family (Bourdon et al., 2005; Marcel et al., 2014) have a major
impact on the p53 properties, collectively defining functions
previously ascribed to a single full length protein. While these
components are undoubtedly important for the p53 genomic
binding and transcription regulation, they function in the context
of chromatin, which plays an active role in transcription and
moderates the interactions with DNA (Li et al., 2007).
p53 NETWORK COMPLEXITY
The p53 ability to load histone modifiers and chromatin remod-
elers upon binding to genomic targets is essential for the tran-
scription regulation (Figure 1) and has been well documented
(Beckerman and Prives, 2010; Rinn and Huarte, 2011). The
opposite, the effect of the chromatin context on p53 targets selec-
tivity is far less understood. Just as transcription factor binding
affects the local chromatin, the chromatin context affects the
transcription factor binding (Guertin and Lis, 2013). Genomic
binding dependent on the chromatin context has been reported
for proteins such as Myc (Guccione et al., 2006) and NFκB
(Natoli, 2009). The chromatin state matters because it is plastic
and dynamic, changing during normal development (Mikkelsen
et al., 2007) and in cancer (Baylin and Jones, 2011). The chro-
matin context introduces a level of complexity in the p53 net-
work, which needs to be considered to understand the p53
functions dependent on DNA binding. Even in a “competent
state” for sequence-specific DNA binding (without mutations,
activated by posttranslational modifications), p53 may not bind
to sites buried in inaccessible chromatin, and bind if they become
available. Despite the proposed and observed chromatin impact
on p53 binding (Lidor Nili et al., 2010; Millau et al., 2011),
there is no good understanding of how p53 binding sites avail-
ability is defined and how it affects the genomic targets selec-
tion. Analysis of the binding context relies on the binding sites
detection.
p53 GENOMIC BINDING SITES
Broadly, two types of experiments provide binding sites informa-
tion, individual gene studies and genome-wide studies. Evidence
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for p53-occupied genomic sites came first from individual gene
studies. About 200 such sites were reported (Horvath et al.,
2007; Riley et al., 2008; Wang et al., 2009). Hereafter these
are called reference REs (response elements), since p53 binding
at them was demonstrated to evoke transcriptional response.
Development of the sequencing technologies enabled genome-
wide studies at unprecedented depth, allowing mapping of
global binding patterns and chromatin state analysis (Park,
2009; Landt et al., 2012), including large scale p53 binding
studies.
Since the discovery of the p53 consensus motif RRRCWW-
GYYY-N(0−13)-RRRCWWGYYY (El-Deiry et al., 1992; Funk et al.,
1992), efforts were focused on designing methods for robust
detection of p53 occupied sites. Early work (Tokino et al., 1994),
followed by limited scale studies (Cawley et al., 2004; Chen and
Sadowski, 2005; Hearnes et al., 2005; Kaneshiro et al., 2007), gen-
erated data allowing extrapolation to the whole human genome.
The estimated 1,500–3,500 sites occupied genome-wide, were in
agreement with predictions by computational models (Veprint-
sev and Fersht, 2008). The first high-throughput p53 ChIP-
PET approach based on Sanger and 454 sequencing (Ng et al.,
2006; Wei et al., 2006) paved the road for the next-generation
sequencing p53 studies. Most of them used ChIP-seq to map
endogenous wild type p53 genomic binding in human cell lines
(Botcheva et al., 2011; Smeenk et al., 2011; Nikulenkov et al., 2012;
Menendez et al., 2013; Akdemir et al., 2014; McDade et al., 2014;
Rashi-Elkeles et al., 2014); some mapped p53 family members,
p53 mutants, or p53 variants (Kouwenhoven et al., 2010; Koeppel
et al., 2011; Martynova et al., 2012; Schlereth et al., 2013; Wang
et al., 2014); others looked at p53 binding in the mouse genome
(Li et al., 2012; Kenzelmann Broz et al., 2013), and recently
p53 binding data were generated by ChIP-exo (Chang et al.,
2014).
FIGURE 1 | Schematic representation of p53 ability to load histone
modifiers upon binding to genomic targets, followed by recruitment or
exclusion of RNA polymerase II (RNAPII), and transcription regulation.
Illustrated is transcription activation upon loading of histone
acetyltransferases (HATs) to promoters of genes regulating cell cycle or
apoptosis, and transcription repression upon loading of histone
deacetylases (HDACs), or through lincRNAs. Based on recent reviews
(Beckerman and Prives, 2010; Rinn and Huarte, 2011).
DEFAULT AND DISTINCT BINDING
What these studies revealed about the endogenous wild type p53
binding to the human genome? Genomic binding is not always
followed by transcription changes; p53 exhibits both “default” and
“distinct” binding. The studies coupled with expression analysis
agreed that many p53 occupied sites are not associated with
transcription changes (Li et al., 2012; Nikulenkov et al., 2012;
Kenzelmann Broz et al., 2013; Menendez et al., 2013; Akdemir
et al., 2014; McDade et al., 2014; Rashi-Elkeles et al., 2014), which
could be interpreted as absence of transcription regulation at
these sites. Since p53 has induced and constitutive functions, and
binding may serve to induce transcription, but also to maintain
basal transcription levels (Zheltukhin and Chumakov, 2010), p53
occupancy at some of these sites may support the basal expression
of the nearby genes. Although not manifested by impressive tran-
scription changes, maintaining global gene expression patterns,
ensuring functional homeostasis under stress, in the damaged
genome, may represent important p53 function. Since p53 binds
to enhancers (Melo et al., 2013), occupancy at some of these sites
may exert long distance effect on gene expression.
p53 ability to induce stress and cell type specific responses is
well recognized, but whether p53 binds to its targets in such selec-
tive manner has been a subject of debate. Recent genome-wide
binding studies revealed common and distinct binding patterns.
Interestingly, treatment with Nutlin (small molecule activator of
p53) leads to more p53 binding, but less effect on transcription,
compared to DNA damage (Nikulenkov et al., 2012; Menendez
et al., 2013). A “p53 default program” was proposed to explain the
observation that the most frequently occupied p53 sites were the
same after different treatments (Nikulenkov et al., 2012). Besides
the detected p53 at common sites, distinct binding patterns were
observed as well (Botcheva et al., 2011; Menendez et al., 2013;
Akdemir et al., 2014).
The proposed “p53 default program” can explain the occu-
pancy at canonical targets (such as CDKN1A and MDM2), consis-
tently reported bound under many stress conditions and cell types
analyzed. On the other hand, significant fraction of the binding
sites displays occupancy dependent on the type of treatment
(Menendez et al., 2013; Akdemir et al., 2014), or on the cell
context (Botcheva et al., 2011; Botcheva and McCorkle, 2014).
If the “default” binding sites are strong, unambiguously detected
by many, and reported “functional,” therefore clearly important
for the transcription regulation, why obsessing with the “distinct”
binding patterns, which despite being shaped by a large fraction
of the data, may be composed by sites with less well defined
individual contribution to direct transcription regulation? The
“default” binding sites, being consistently occupied, may reflect
fundamental p53 functions important in any cell context or stress
type, while the distinct binding patterns may reveal more about
the stress- and cell type- specific p53 functions. Patterns matter in
nature. For example, despite the importance of individual popula-
tions for biodiversity, gross changes in tropical forests have major
impact on earth climate (Lewis, 2006). In order not to lose the
forest for the trees, it may be worth studying the global patterns
associated with p53 binding, since these may reflect global trends
in the binding context, affecting the way p53 network is engaged
in response to stress.
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THE CHROMATIN CONTEXT
What causes the distinct genomic binding patterns of the endoge-
nous wild type p53? Cancer-derived human cell lines have been
widely used for p53 research (Millau et al., 2010). When high-
resolution p53 binding map was generated for the first time in
normal, not immortalized human cell line (Botcheva et al., 2011)
and compared to previous studies in cancer cell lines (Wei et al.,
2006; Smeenk et al., 2008, 2011), distinct p53 binding patterns
were observed. Only in the normal cells p53 was strongly enriched
within 2 kb of transcription start sites and at CpG islands (CGIs);
distribution typical for the functional reference REs, but not for
the sites mapped in the cancer cell lines, where p53 was depleted
from CGIs. The chromatin structure at CGIs is important for
the regulation of transcription; these CG rich sequences are kept
hypomethylated in otherwise methylated genome, and subjected
to epigenetic control (Deaton and Bird, 2011). Correlating p53
binding with high-resolution methylome generated in the same
cell line (Lister et al., 2009), revealed enrichment of p53 binding
sites at hypomethylated DNA. Importantly, that was true not
only for sites in CGIs (generally kept hypomethylated), but for
sites out of CGIs as well (Botcheva et al., 2011). Notably, when
p53 DNA binding in methylation-dependent mode was first con-
sidered and examined, no specific p53 affinity was detected for
particular methylation state of the binding sites on naked DNA
(Petrovich and Veprintsev, 2009). Thus, p53 propensity to bind
at hypomethylated regions (not just CGIs) was likely due to the
chromatin structure modulated by the DNA hypomethylation,
rather than affinity to hypomethylated binding site (Botcheva
et al., 2011), although at present that could not be excluded.
Due to the nature of the distinct p53 binding patterns (enrich-
ment at hypomethylated DNA and CGIs in the normal cell line;
depletion from CGIs and higher enrichment at repeats in the can-
cer cell lines), it was proposed that epigenetic changes accompany-
ing cancer progression (local CGIs hypermethylation and global
genomic hypomethylation) modulate p53 binding to the genome
(Botcheva et al., 2011). Another possibility suggested that at
certain sites, the methylated CpGs may undergo tumorogenesis-
dependent deamination, to eliminate p53 responsiveness (Freed-
Pastor and Prives, 2011). Subsequently, a key study in mouse
fibroblasts revealed that in absence of wild type p53, DNA
demethylation triggers repeats instability, followed by massive
apoptotic response (Leonova et al., 2013), commented in details
(Levine and Greenbaum, 2012; Koonin, 2013; Tavana and Gu,
2013). These findings have implications beyond gene promoters
and repeats, because cancer is accompanied by global epigenetic
alterations involving enhancers and insulator elements as well
(Taberlay et al., 2014), and binding at enhancers is important for
the p53-dependent transcription regulation.
The datasets analyzed by Botcheva et al. (2011) differed not
only by cell context (normal and cancer-derived cell lines), but
by treatment and/or experimental approach, potentially con-
tributing to the observed p53 binding differences. Recently, the
distinct p53 binding patterns were confirmed under same treat-
ment, experimental conditions and ChIP-seq approach, evidence
for cell context-dependent p53 genomic binding (Botcheva and
McCorkle, 2014). Moreover, the analysis was extended to examine
the differentially bound types of repeats and p53 was found
enriched at LINE (long interspersed nuclear elements) in the can-
cer cell line HCT116, compared to the normal IMR90 (Botcheva
and McCorkle, 2014). Epigenetic dysregulation at repeats is a
major cancer landmark, and hypomethylated LINE repeats (nor-
mally methylated) are associated with bad colon cancer prognosis
(Ogino et al., 2008); thus, p53 enrichment at LINE repeats in the
colorectal cell line HCT116, might be due to cancer-associated
LINE hypomethylation (Botcheva and McCorkle, 2014). The
distinct p53 binding patterns in HCT116 and IMR90 likely reflect
differences in the epigenetic landscapes in these cell lines, due to
cancer-associated changes (accumulated in HCT116), overlaid on
tissue-specific differences (HCT116 has epithelial, while IMR90
has mesenchymal origin; Botcheva and McCorkle, 2014). In the
future, it would be very interesting to investigate the involvement
of the p53 transcriptional network in the process of cancer-
associated EMT (epithelial mesenchymal transition).
SENSING THE EPIGENOME
The epigenetic impact on p53 genome-wide binding (Botcheva
et al., 2011), and p53-dependent transcription regulation
(Leonova et al., 2013) has far reaching implications. The p53
genomic targets selection is important for tumor suppression, yet
the mechanisms are unclear. These studies suggest p53 genomic
binding dependent on DNA methylation (Figure 2). While it
is known that transcription factor binding can be affected by
the methylation status of the CpGs in their binding sites (Chen
et al., 2011), the probable mechanisms remain to be defined.
Interestingly, although the OCT4 motif does not contain CpGs, in
human embryonic stem cells this protein is excluded from target
sites residing in DNA methylated locations (You et al., 2011; Jones,
2012).
p53 has been long known as a keeper of the genomic
integrity, and sensing the epigenome might be important part of
it. While searching for binding sites, p53 may be “screening”
the genome for DNA hypomethylation at regions “normally”
FIGURE 2 | Schematic representation of wild type p53 binding to
genomic targets in a DNA methylation-dependent manner. In normal
cells the stress-induced p53 binds to sites residing in hypomethylated
regions. Cancer-associated epigenetic changes may lead to local p53
depletion from hypermethylated target promoters and enrichment at
globally hypomethylated regions, such as repeats (Botcheva et al., 2011;
Botcheva and McCorkle, 2014).
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hypermethylated (residing in inaccessible chromatin context),
which would become available for p53 binding upon hypomethy-
lation. Global DNA hypomethylation on a large scale could expose
numerous sites, causing global redistribution of the p53 binding
and readjusting its transcriptional program to maintain genomic
stability.
While “guarding the genome” does not involve direct recogni-
tion of genetic lesions by p53, sensing the epigenome may imply
direct recognition of the regions of epigenetic changes. Moreover,
the extensive network of p53 binding sites at repeats (Wang et al.,
2007; Harris et al., 2009; Zemojtel et al., 2009; Cui et al., 2011;
Botcheva and McCorkle, 2014) could serve as a system of sensors
for detection of epigenetic perturbations, which could destabilize
the repeats and the whole genome. Therefore, the reason for
the existence of p53 binding sites at repeats may be monitoring
for epigenetic aberrations. Upon comparing p53 binding in can-
cer cell lines under different stress, common global trends may
emerge (besides the “default program”) that are dependent on
the epigenetic changes, shared at least to some extent by these
cell lines. Considering the magnitude of such epigenetic changes,
the common trends could dominate the p53 binding landscape,
obscuring the detection of more subtle stress-specific patterns and
making the binding look “non-selective.”
p53 has been regularly reported bound to some of its genomic
targets in absence of stress, often interpreted as allowing for fast
transcriptional response upon stress induction. Considering the
p53 binding at hypomethylated DNA, it is possible that p53
occupies constitutively some of its key targets to protect them
from hypermethylation, which may make them inaccessible for p53
binding, abrogating its tumor suppression program.
Mammalian cells acquire epigenetic hallmarks of human can-
cer during immortalization (Tommasi et al., 2013). If p53 indeed
is sensing the epigenome at the level of genomic binding, one
may expect p53 binding patterns in immortalized cells to be more
similar to those in cancer cells, rather than to those in normal
cells. In support of that, ChIP-chip study examining p53 binding
in different cell contexts demonstrated that immortalized fibrob-
lasts behaved as cancer cell lines, unlike the normal cells (Shaked
et al., 2008). Studying the changing p53 binding patterns during
immortalization could reveal information about the epigenetic
modulation of the p53 network functions early in tumorogenesis.
Do these findings have clinical implications? In certain con-
texts, wild type p53 may serve “oncogenic” functions and may
not need further activation. Interestingly, there are colorectal
cancer subgroups with CGI methylator phenotype (CIMP-high,
CIMP-low) less likely to accumulate p53 mutations (Hinoue et al.,
2012). It may be because they need wild type p53 to protect
them from the deleterious effects of aberrant DNA methylation.
In such cases, use of demethylating agents could be explored. One
such drug, Decitabine, has been approved by FDA since 2006 for
treating myelodysplastic syndromes, and has shown promising
results on epithelial tumor cells as well (Tsai et al., 2012).
CROWD CONTROL NAVIGATION
The high-confidence p53 binding sites annotated by a given
genome-wide study represent only a small subset of the total
sites detected; the vast majority of the sites are not associated
with particular function. Considering the degenerate p53 con-
sensus binding motif, computational models estimate hundreds
of thousands sites in the human genome (Hoh et al., 2002;
Veprintsev and Fersht, 2008). Why so many, if only few are func-
tional? Degenerate binding motifs are often found for sequence
specific DNA binding proteins in higher eukaryotes, unlike in
prokaryotes (Kadonaga, 2004). Interestingly, despite the smaller
genome, prokaryotic transcription factors have more specific
binding motifs; despite the larger genomes, eukaryotic tran-
scription factors have degenerate, lower specificity DNA binding
motifs. Applying information theory to the genomic sites recog-
nition by DNA binding proteins, minimum information content
is required to specify unique position in the genome. Calculations
of the average information content of prokaryotic and eukaryotic
motifs (based on the motif length and the base frequency at
particular positions) demonstrated that in prokaryotes single
binding site is sufficient to address unique location in the genome,
but not in eukaryotes (Wunderlich and Mirny, 2009). The average
information content of a prokaryotic motif I ≈ 23 bits is slightly
above the required Imin ≈ 22 bits to specify unique position
in a prokaryotic genome (106–107 bp); the average information
content of a multicellular eukaryotic motif I ≈ 12.1 bits is far
below the minimum information required Imin ≈ 30 bits to specify
unique position in eukaryotic genome of ∼109 bp (Wunderlich
and Mirny, 2009).
One may expect that eukaryotic DNA binding proteins, locat-
ing their sites in larger genomes, would have motifs with higher
information content than prokaryotes. Instead it is the opposite.
Because of motifs degeneracy, numerous DNA binding sites,
besides the “functional” ones, are present for a given DNA
binding protein (p53 including). Thus, “functionality” is spec-
ified by additional means, such as clustering of binding sites,
combinatorial and cooperative binding (Kadonaga, 2004), and
three-dimensional organization of the chromatin (Lieberman-
Aiden et al., 2009; Edelman and Fraser, 2012; Amouyal, 2014).
The point is, why on the first place, eukaryotic DNA binding
proteins evolved to have degenerate motifs, meaning promiscuous
binding to the genome, and requiring additional means to spec-
ify functionality? Why not evolving higher content information
motifs which would specify unambiguously unique positions in
the genome? It may be because the unique positions have to be
not only specified, but found in the large genome.
The mode employed by eukaryotic DNA binding proteins to
find their genomic sites may make sense from navigation point
of view. According to current models for DNA binding sites
search (Halford and Marko, 2004), and by p53 (McKinney et al.,
2004; Tafvizi et al., 2011), a protein spends time “on” and “off ”
DNA, and “moving along DNA” is important (here, terms as
“sliding” and “diffusing” are omitted since the point is not about
how a protein propels on DNA, but how it navigates it). There
are many DNA binding proteins presumably searching for their
“functional” sites on DNA (Zabet and Adryan, 2013). It may
look contra intuitive but the many degenerate binding sites, by
transiently binding their cognate proteins, may actually serve the
role to navigate and ensure “smooth traffic” on DNA, so that the
“functional” sites could be reached efficiently (in everyday life,
traffic lights and stop signs are placed in the most crowded traffic
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spots). Interestingly, “crowd control” theories have been long
applied to animal kingdom and group decision making has been
hypothesized to be beneficial in complex environments (Berdahl
et al., 2013). It is possible that the DNA binding proteins in
the large eukaryotic genomes rely on “crowd control navigation”
provided by the multiple binding sites, in order to reach their
“functional” binding sites and regulate transcription.
CONCLUSION
The p53 network is perfectly fit to be interrogated by genome-
wide approaches. That would allow otherwise hidden global
patterns to be revealed and studied, to help interpreting the
p53-dependent tumor suppression program in the context of
dynamic chromatin and to dissect the interplay between genetic
and epigenetic changes associated with cancer. The discoveries
from the past 35 years expanded greatly the p53 knowledge and
underlined the importance of addressing the p53 network com-
plexity for the pathway’s full potential to be unlocked and applied
in the clinic, because cancer progression and tumor suppression
are two faces of the same coin and the p53 mark is undeniably
stamped on both.
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